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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 















• A systematic review and 
meta-analysis was 
conducted to explore 
possible risk factors for 
severe COVID-19.  
• Two authors 
independently screened 
for articles. The 
Newcastle-Ottawa Scale 
was used to evaluate 
quality. Forty-one (41) 
articles were included and 






• From pooled results, 
being male, being of 
advanced age, having 
history of smoking, and 
higher BMI 
(>_30kg/m2),  were 
considered risk factors for 
severe disease. 
• Seven (7) co-morbidities 







of severe disease, these 
included: Chronic Kidney 
Disease, Chronic 
Obstructive Pulmonary 




and chronic liver diseases. 
There was no significant 
difference in severe vs 
non severe COVID-19 
disease in patients with 
asthma. 




Syndrome, shock and 
















• Mortality and morbidity 
outcomes for patients 
admitted to Intensive Care 
Units (ICU) with severe 
COVID-19 infection have 
been reported, however, 
the authors report that 
only one other study 
specifically explores ICU 
outcomes in Africa. To 
address this gap, the 
authors present data from 
a prospective cohort study 
across 11 ICUs in Libya, 
from 29.05.2020 to 
30.12.2020. Adult patients 
included (n=465) were 
followed up for 60 days 
from ICU admission or 
until discharge. 
• At 60 day follow up, 
60.4% (281/465) of 
patients had died in the 
ICU, and 39.6% (184/465) 
were discharged. In 
comparing these two 
groups, multivariant 
analysis showed lower 
lymphocyte count, higher 
procalcitonin, cardiac 
troponin, C-reactive 
protein, D-dimer, total 











emergency intubation and 
stress cardiomyopathy 
were significantly 
associated with mortality. 
• The study also found that 
those aged > 70 years 
had the highest mortality 
rate compared to the other 
age groups. Use of 
antibiotics was associated 
with lower mortality. 
• The study reports that the 
study  ‘demonstrated the 
utilization of both the 
SOFA score and quick 
SOFA score at admission. 
The results found a 
median (IQR) quick SOFA 
score of 1 (1–2) and a 
total SOFA score of 6 (4–
7) on admission’, and 
indicates the severity 
within the cohort. The 
authors report that some 
patients would have 
waited hours or days for 
an ICU bed due to lack of 
capacity during the surge 
in number of cases, which 
may have contributed to 
the SOFA scores and the 
higher mortality. The 
authors also report that 
other factors such as 
human resources and 
shortage of medical 
supplies, as well as the 
ongoing civil war and 
severe financial crisis 
should be considered, and 
therefore healthcare 
system challenges need 
to be addressed to 
support health workers 
and response during 
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• This study uses nationwide 
surveillance data in Israel to 
explore SARS-CoV2 
outcomes following two 
doses of the BNT162b2 
vaccine (Pfizer–BioNTech 
mRNA) for people over 16 
years of age. Surveillance 
data from 24.01.2921 to 
03.04.2021 was analysed. 
People were considered 
fully vaccinated if at least 7 
days past receiving second 
vaccination. At the time, 
4 714 932 (72·1%) of 
6 538 911 people aged 16 
years or older and 1 015 620 
(90·0%) of 1 127 965 people 
aged 65 years or older were 
fully vaccinated with two 
doses.  Outcomes analyses 
included; symptomatic and 
asymptomatic cases of 
COVID-19, hospitalised with 
COVID-19, severe/critical 
cases of COVID-19, and 
deaths. B.1.1.7 was 
reported as the dominant 
strain during this period. 
• During this time period;  
o 232 268 SARS-CoV-2 
infections were confirmed, 
and 66.6% were in people 
over 16 years.  Out of this 
group (154 648), 71% 
were unvaccinated and 
4.1% fully vaccinated. 
o 54 677 people aged 16 
years and older who had 
symptomatic COVID-19, 
71·4% (39 065)  were 
unvaccinated and 3·1% 
(1692) received two doses. 
o 7694 people aged 16 
years and older who were 
hospitalised with COVID-










ss, Israel  
unvaccinated and  7·7% 
(596) received two doses. 
o 4481 COVID-19-related 
severe or critical 
hospitalisations occurred in 
people aged 16 years and 
older, among which 71·4% 
(3201) people were 
unvaccinated 
and  8·1%  (364) were fully 
vaccinated. 
o 1113 people aged 16 
years and older who died 
from COVID-19, 64·2% 
(715)  were unvaccinated 
and 12·4% (138) were fully 
vaccinated. 
• The authors report that ‘the 
adjusted estimates of 










against severe or critical 
hospitalisation, and 96·7% 
(95% CI 96·0–97·3%) 
against death.’ 
• Vaccine effectiveness 
against deaths was 
estimated to be 98·1% at 14 
days or longer after the 
second vaccine, and 77·0·% 
at 14–21 days after the first 
vaccine. 
• The authors conclude, that 
vaccination with two doses 
of BNT162b2 has high 
efficacy and effectiveness 
against a range of SARS-
CoV-2 outcomes, including 
among older adults (aged 
≥85 years). 







• This paper reports on Phase 
2 trials with NVX-CoV2373 
(Novavax) in South Africa 
with people HIV negative, 











who are medically stable 
HIV positive. Participants 
were recruited from across 
16 sites in South Africa, and 
were aged 18-84 years if 
HIV negative and 18-64 
years if HIV positive. 
Participants either received 
the vaccine or a placebo in 
1:1 ratio and were followed 
up 7 days, 21 days, 35 days, 
3 months and 6months. 
• 4387 participants were 
included and received at 
least one vaccine or 
placebo. 30% were 
seropositive for COVID-19 
at baseline. 
• Among vaccine recipients, 
adverse events reported 
included; headache (20 to 
25%), muscle pain (17 to 
20%), and fatigue (12 to 
16%). 
• 2684 participants who were 
COVID-19 seronegative at 
baseline were included in 
analysis for vaccine efficacy 
(94% HIV negative, 6% HIV 
positive). After 28 days, 15 
participants in the vaccine 
group and 29 participants in 
the placebo group 
developed symptomatic 
COVID-19. All (except one 
person) were classified as 
mild/moderate COVID-19. 
The authors report vaccine 
efficacy of 49.4%. Vaccine 
efficacy among HIV-
negative participants was 
60.1%. Post hoc vaccine 
efficacy against B.1.351 was 
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• A modelling study was 
designed to explore the 
potential impact of short-
term lockdowns due to 
COVID-19 on Tuberculosis 
(TB), focusing on India, the 
Republic of Kenya and 
Ukraine. Different models 
explored difficult scenarios 
including; 2 month lockdown 
followed by 2 month 
recovery and 3 month 
lockdown followed by 10 
month recovery (worst case 
scenario). Global estimates 
were also made. 
• The authors summarise 
‘Each month taken to return 
to normal TB services would 
incur, in India, an additional 
40,685 deaths between 
2020 and 2025; in Kenya, an 
additional 1,157 deaths; and 
in Ukraine, an additional 137 
deaths over this period.’ 
• For the worst case scenario, 
the authors report that this 
could lead to an additional 
6.3 million cases of TB  and 
additional 1.4 million deaths 
due to TB between 2020-
2025. 
• Increase efforts and 
investment are therefore 
needed to mitigate against 
this. Measure suggested are 
intensifying active case 
finding, community 
engagement and contact 
tracing, and increasing 
































• Vaccination is an important 
strategy during the COVID-
19 pandemic. The target of 
the COVID-19 Vaccine 
Development and Access 
Strategy (Africa CDC 2020) 
is to vaccinate 60% of the 
population in Africa by 
2022. Survey data across 
22 African  countries was 
analysed to explore public 
perception towards COVID-
19 vaccinations to inform 
vaccination programmes. 
The five large scale surveys 
included over 12 million 
respondents between 
March 2020 and March 
2021. Whilst key differences 
between the survey 
methodologies and 
limitations were 
acknowledged, the authors 
report the following key 
results: 
o Overall vaccine 
acceptance was 
considered quite high, but 
variable across countries 
and type of survey. 
Guinea had the highest 
acceptance (86%) whist 
Cameroon had the lowest 
(35%). 
o A large CDC survey 
indicated no overall 
gender difference in 
vaccine hesitancy, whilst 
smaller studies indicated 
women were more vaccine 
hesitant compared to men. 
Other demographic factors 
did not appear to have an 
impact on vaccine 
acceptance, although 
some studies reported 









older participants, higher 
economic groups or higher 
education group. 
o In many of studies, 
personal risk of COVID-19 
infection was perceived to 
be low, and there were 
concerns about the safety 
of the vaccine. This 
included: beliefs that the 
development of the 
vaccine was rushed; fear 
of side effects; beliefs 
about ingredients; and 
distrust over the mRNA 
technology used. 
o There were some 
concerns about who will 
be prioritised for 
vaccination, potential cost 
implications and fear and 
distrust of potential 
mandatory vaccination 
strategies. There was also 
some mistrust about 
vaccine procurement 
within the context of 
geopolitics. 




vaccines. The CDC 
reported that 66% of 
participants believe they 
have been exposed to 
them. There were also 
some reports of the need 
for more information of the 
vaccines. 
o There was some 
relationship between trust 
in governments and trust 
in the vaccine.  
o COVID-19 had a negative 
impact on routine 
vaccinations. 















Recognising the challenges of 
International Health Regulations 
framework, Duff et al propose 10 
recommendations to strengthen 
global health governance in 
pandemic response. These 10 
recommendations were 
developed through qualitative 
interviews with a panel of 
experts. Recommendations for 
global health security include: 
• Greater authority for a 
global governing body 
• Greater capacity for global 
health system (and 
agencies) to be flexible 
and rapidly respond to 
diverse needs. 
• A central body with 
technical expertise that is 
‘empowered to create and 
communicate the 
standards for the world 
without undue political 
interference’. 
• An objective evaluation 
system for national core 
public health capacities. 
• Governing body (bodies) 
with the ability to enforce 
standards through effective 
enforcement mechanisms. 
• Autonomous governing 
body (bodies) with freedom 
of self-governance and 
decision making processes 
resistant to undue political 
pressures. 
• Sustainable financing 
• A governance structure 
which is representative of 
all countries, with a high 










• Multi-sector collaboration 
at all levels of governance. 
• Collective commitment and 
action from all countries. 
The authors recognise that 
implementing these 
recommendations may involve 
reforming and strengthening 
WHO, concluding, ‘the lessons 
learned from the COVID-19 
pandemic response efforts 
present a unique chance to re-
evaluate, refocus, and revise the 
current global public health 




















• The article reflects on the 
early response of agencies 
in West Africa to mitigate 
against the COVID-19 
pandemic. In comparison to 
other global regions, West 
Africa has had relatively few 
COVID-19 cases, for 
example, as of March 2021, 
5363 deaths were reported 
compared to the USA (with 
a similar size population) 
having 530, 000 deaths. 
The authors outline the 
response of West Africa to 
mobilise resources and 
leverage on systems and 
infrastructure developed 
during previous epidemics. 
• Pan-African institutions and 
mechanisms were mobilised 
such as the African Centre 
for Disease Control. 
Regionally,  the Economic 
Community of West African 
States (ECOWAS) Regional 
Centre for Surveillance and 











following the Ebola 
epidemic to prepare and 
respond to current and 
future pandemics. Other 
institutions established 
include a Ministerial 
Coordination Committee 
and a network of Public 
Health Reference 
Laboratories. 
• In Jan 2020, 15 ECOWAS 
countries met to strengthen 
critical national capacities. 
Funds were also mobilised 
through country-specific and 
multi-country initiatives. This 
funding went to response 
measurements like the 
provision of resources and 
equipment, and also to the 
provision of social safety 
nets for vulnerable 
populations. 
• At the start of the pandemic, 
the region had two 
laboratories for diagnosis of 
COVID-19 which has now 
expanded to all countries 
(since September 2020). 
Research and surveillance 
capacities have also been 
strengthened. 
• Despite these successes, 
the authors caution against 
complacency as this is an 
evolving pandemic with the 
ability to overwhelm health 
systems, as seen 
elsewhere, and they 
advocate for increased 
support and investment in 
increasing testing capacity, 
information management 
systems, human resource 
capacity and research and 
development  in health 
technologies, such as local 
vaccine production capacity. 
This would support the 
region to respond to 
COVID-19 and future 
pandemics. 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
08.05.2021 India’s covid-19 catastrophe is a failure of national and global 
public health and policy response to the pandemic 
The BMJ| Opinion 
blog 
07.05.2021 Where are we with drug treatments for covid-19? The BMJ| Feature 
Briefing 
07.05.2021 Management of severe covid-19: progress and promise The BMJ| Editorials 
06.05.2021 Priorities for COVID-19 research response and 
preparedness in low-resource settings 
The Lancet| Comment 
06.05.2021 Amitava Banerjee: Covid-19 in India—lockdown and 
vaccination drive only way forward 
The BMJ| Opinion 
blog 
06.05.2021 Covid-19: Two doses of Pfizer vaccine are “highly effective” 
against infection, hospital admission, and death, study finds 
The BMJ| News 
06.05.2021 Pandemic preparedness in the 21st century: which way 
forward? 
The Lancet Public 
Health | Comment 
05.05.2021 Supply-chain strategies for essential medicines in rural 
western Kenya during COVID-19 
WHO Bulletin| 
Lessons from the field 
05.05.2021 COVID-19 rise in Bangladesh correlates with increasing 
detection of B.1.351 variant 
BMJ Global Health | 
Editorial 
05.05.2021 Thromboembolism and the Oxford-AstraZeneca vaccine The BMJ| Editorials 
04.05.2021 Covid-19: Bolsonaro tells Brazilians to stop “being a country 
of sissies’’ 
The BMJ| Opinion 
blog 
04.05.2021 Time for the ethical management of COVID-19 vaccines The Lancet Global 
Health| Viewpoint 
30.04.2021 Why is India having a covid-19 surge? The BMJ| News 
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  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
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Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     




 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 
  Science  Health systems 
Global 





  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
20.05.2021 COVID-19: What 
Impacts on UHC in 
Africa? 




Lives in the Balance: 
Equity in COVID-19 
Recovery 
Summit 2 days PMNCH, Global 
Financing Facility for 
Women, Children 
and Adolescents 
(GFF), Gavi, the 




Research Behind the 
Pandemic 
Course 2 weeks 
(4 hrs) 
Future Learns 
13.05.2021 Covid and mental 
health 
Webinar 2h 15 BMJ 
15.04.2021 How can evaluation 
work support greater 
vaccine equity for 
COVID-19? 
Webinar 1h Itad 
12.04.2021 COVID-19: Vaccines 
Safety Webinar - 
Understanding the 
Facts & Myths 
Webinar 1.5h Asia Pacific 
Association of 
Allergy, Asthma and 
Clinical Immunology 
07.04.2021 Public webinar 'The 
RECOVERY Trial: one 
year on' 
Webinar 1h Nuffield Department 
of Population Health 
25 March 
2021 
UK Public Health Rapid 
Support Team: Latest 
research & scientific 
insights 
Webinar 1h LSHTM 
18 March 
2021 
Africa taking charge of 
its future: prioritizing 
gender equality in the 
path to recovery 
Webinar 1h 30 CGD 
10 March 
2021 
Equity and scale in 
global immunization: 
new evidence from 
Nigeria on cash 
transfers for vaccination 
Webinar 1h 15 CGD 
9 March 
2021 
COVID-19 vaccines and 
Africa: where do we 









Diseases in the COVID 
era 




training for health 
workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during the 
COVID-19 pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply chain 
resilience and global 
trade 
Webinar 1h CGD 
03.12.2020 More money for health 
services: What is the 
tole of PFM in the “new 
normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental wellbeing 
of community health 
workers on the COVID-
19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the 




  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to promote 
sharing of experience 
and expertise around 




starting 16 Nov 
  HIFA 
services during (and 
after) the pandemic 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the Economic 
and Health Impact of 
COVID-19 across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online courses 
related to COVID19. 










Nursing in Times of 
Crisis 






School of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 




Modelling and Policy 
Online learning 2 weeks 








11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 




Virtual Evidence Weeks 5 sessions 1h 30 International Initiative 










COVID-19 Open online 
brief with Dr David 
Nabarro 





COVID-19: methods for 
detection, prevention, 
response and control 




19: Real-time training 
for the coronavirus 
disease outbreak 







COVID-19: Tackling the 
Novel Coronavirus 
Online learning 3 weeks 












Online learning 3 weeks 









6 April 2020 COVID-19 Critical Care: 
Understanding and 
Application 
Online learning 5 weeks 





Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary 
research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease 
control and health system responses are included. Articles related to tackling the secondary impacts on other 
sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on 
relevance. 
  
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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